Medicine and HealthNature Medicine
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease
G. Pagano, K. I. Taylor, et al.
This exploratory analysis of the PASADENA phase 2 study highlights prasinezumab's potential as a disease-modifying therapy for early-stage Parkinson's disease. Although the primary endpoint wasn't achieved, findings suggest that prasinezumab may significantly slow motor sign progression in rapidly progressing patients. The research was conducted by prominent authors in the field.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Ingested nitrate and nitrite and end-stage renal disease in licensed pesticide applicators and spouses in the Agricultural Health Study
D. Chen, C. G. Parks, et al.
Medicine and Health
Atypical processing of tones and phonemes in Rett Syndrome as biomarkers of disease progression
O. V. Sysoeva, S. Molholm, et al.
Psychology
The genetic determinants of language network dysconnectivity in drug-naïve early stage schizophrenia
J. Du, L. Palaniyappan, et al.
Psychology
Three-year outcomes and predictors for full recovery in patients with early-stage psychosis
L. Li, F. Z. Rami, et al.
